Cited by 211

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis

Joyce, Johanna A, Laakkonen, Pirjo, Bernasconi, Michele, Bergers, Gabriele, Ruoslahti, Erkki, Hanahan, Douglas·2003·Cancer Cell

Abstract

The vasculature in the angiogenic stages of a mouse model of pancreatic islet carcinogenesis was profiled in vivo with phage libraries that display short peptides. We characterized seven peptides distinguished by their differential homing to angiogenic progenitors, solid tumors, or both. None homed appreciably to normal pancreatic islets or other organs. Five peptides selectively homed to neoplastic lesions in the pancreas and not to islet beta cell tumors growing subcutaneously, xenotransplant tumors from a human cancer cell line, or an endogenously arising squamous cell tumor of the skin. Three peptides with distinctive homing to angiogenic islets, tumors, or both colocalized with markers that identify endothelial cells or pericytes. One peptide is homologous with pro-PDGF-B, which is expressed in endothelial cells, while its receptor is expressed in pericytes.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(03)00271-x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 53

  1. Arap, 1998, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, Science, 279, 377, 10.1126/science.279.5349.377 · DOI
  2. Arbeit, 1994, Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice, J. Virol., 68, 4358, 10.1128/JVI.68.7.4358-4368.1994 · DOI
  3. Bergers, 1998, Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis, Int. J. Dev. Biol., 42, 995
  4. Bergers, 2003, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, J. Clin. Invest., 111, 1287, 10.1172/JCI200317929 · DOI
  5. Bergsten, 2001, PDGF-D is a specific protease-activated ligand for the PDGF β-receptor, Nat. Cell Biol., 3, 512, 10.1038/35074588 · DOI
  6. Betsholtz, 2001, Developmental roles of platelet-derived growth factors, Bioessays, 23, 494, 10.1002/bies.1069 · DOI
  7. Bohme, 1995, Primary structure of the long and short splice variants of mouse collagen XII and their tissue-specific expression during embryonic development, Dev. Dyn., 204, 432, 10.1002/aja.1002040409 · DOI
  8. Borges, 2000, Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain, J. Biol. Chem., 275, 39867, 10.1074/jbc.M007040200 · DOI
  9. Burg, 1999, NG2 proteoglycan-binding peptides target tumor neovasculature, Cancer Res., 59, 2869
  10. Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 · DOI · Paper page
  11. Clements, 1991, Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation, EMBO J., 10, 4113, 10.1002/j.1460-2075.1991.tb04988.x · DOI
  12. Coussens, 1996, Genetic predisposition and parameters of malignant progression in K14–HPV16 transgenic mice, Am. J. Pathol., 149, 1899
  13. Efrat, 1988, Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene, Proc. Natl. Acad. Sci. USA, 85, 9037, 10.1073/pnas.85.23.9037 · DOI
  14. Ellerby, 1999, Anti-cancer activity of targeted pro-apoptotic peptides, Nat. Med., 5, 1032, 10.1038/12469 · DOI
  15. Fulgham, 1999, FGF-2 dependent angiogenesis is a latent phenotype in basic fibroblast growth factor transgenic mice, Endothelium, 6, 185, 10.3109/10623329909053409 · DOI
  16. Gohring, 1998, Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope, Eur. J. Biochem., 255, 60, 10.1046/j.1432-1327.1998.2550060.x · DOI
  17. Hallman, 1995, Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier, Dev. Dyn., 202, 325, 10.1002/aja.1002020402 · DOI
  18. Hanahan, 1985, Heritable information of pancreatic beta-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes, Nature, 315, 115, 10.1038/315115a0 · DOI
  19. Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016/S0092-8674(00)80108-7 · DOI · Paper page
  20. Hashizume, 2000, Openings between defective endothelial cells explain tumor vessel leakiness, Am. J. Pathol., 156, 1363, 10.1016/S0002-9440(10)65006-7 · DOI · Paper page
  21. Heldin, 1999, Mechanism of action and in vivo role of platelet-derived growth factor, Physiol. Rev., 79, 1283, 10.1152/physrev.1999.79.4.1283 · DOI
  22. Hobbs, 1998, Regulation of transport pathways in tumor vessels, Proc. Natl. Acad. Sci. USA, 95, 4607, 10.1073/pnas.95.8.4607 · DOI · Paper page
  23. Hoffman, 2003, Cancer Cell, 4, 383, 10.1016/S1535-6108(03)00273-3 · DOI
  24. Johnsson, 1984, The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor, EMBO J., 3, 921, 10.1002/j.1460-2075.1984.tb01908.x · DOI
  25. Laakkonen, 2002, A tumor-homing peptide with a targeting specificity related to lymphatic vessels, Nat. Med., 8, 751, 10.1038/nm720 · DOI
  26. LaRochelle, 2001, PDGF-D, a new protease-activated growth factor, Nat. Cell Biol., 3, 517, 10.1038/35074593 · DOI
  27. Leppink, 1989, Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration, Transplantation, 48, 874, 10.1097/00007890-198911000-00032 · DOI
  28. Leveen, 1994, Mice deficient for PDGF-B show renal, cardiovascular and hematological abnormalities, Genes Dev., 8, 1875, 10.1101/gad.8.16.1875 · DOI
  29. Lindahl, 1997, Pericyte loss and microaneurysm formation in PDGF-B deficient mice, Science, 277, 242, 10.1126/science.277.5323.242 · DOI · Paper page
  30. Liotta, 2001, The microenvironment of the tumour-host interface, Nature, 411, 375, 10.1038/35077241 · DOI
  31. Lopez, 2002, Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis, Cancer Cell, 1, 339, 10.1016/S1535-6108(02)00055-7 · DOI
  32. Morikawa, 2002, Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors, Am. J. Pathol., 160, 985, 10.1016/S0002-9440(10)64920-6 · DOI
  33. Ngo, 2000, An in vivo function for the transforming Myc protein, Cell Growth Differ., 11, 201
  34. Oh, 1993, Tissue-specific expression of type XII collagen during mouse embryonic development, Dev. Dyn., 196, 37, 10.1002/aja.1001960105 · DOI
  35. Ornitz, 2001, Fibroblast growth factors, Genome Biol., 2, 3005, 10.1186/gb-2001-2-3-reviews3005 · DOI
  36. Ostman, 2001, Involvement of platelet-derived growth factor in disease, Adv. Cancer Res., 80, 1, 10.1016/S0065-230X(01)80010-5 · DOI
  37. Ostman, 1991, Identification of three amino acids in the platelet-derived growth factor (PDGF) B-chain that are important for binding to the PDGF-β receptor, J. Biol. Chem., 266, 10073, 10.1016/S0021-9258(18)99191-X · DOI
  38. Parangi, 1995, Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma, Cancer Res., 55, 6071
  39. Pasqualini, 1996, Organ targeting in vivo using phage display peptide libraries, Nature, 380, 364, 10.1038/380364a0 · DOI
  40. Pasqualini, 2000, Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis, Cancer Res., 60, 722
  41. Plotnikov, 1999, Structural basis for FGF receptor dimerization and activation, Cell, 98, 641, 10.1016/S0092-8674(00)80051-3 · DOI
  42. Porkka, 2002, A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo, Proc. Natl. Acad. Sci. USA, 99, 7444, 10.1073/pnas.062189599 · DOI
  43. Rajotte, 1998, Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display, J. Clin. Invest., 102, 430, 10.1172/JCI3008 · DOI
  44. Roberts, 1998, Host microvasculature influence on tumor vascular morphology and endothelial gene expression, Am. J. Pathol., 153, 1239, 10.1016/S0002-9440(10)65668-4 · DOI
  45. Ruoslahti, 2002, Specialization of tumour vasculature, Nat. Rev. Cancer, 2, 83, 10.1038/nrc724 · DOI
  46. Sato, 1993, Tie-1 and Tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system, Proc. Natl. Acad. Sci. USA, 90, 9355, 10.1073/pnas.90.20.9355 · DOI
  47. Schlingemann, 1990, Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds, Am. J. Pathol., 136, 1393
  48. Schlingemann, 1991, Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissues, Am. J. Pathol., 138, 1335
  49. Somasundaram, 1996, Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB), J. Biol. Chem., 271, 26884, 10.1074/jbc.271.43.26884 · DOI
  50. Soriano, 1994, Abnormal kidney development and hematological disorders in PDGFβ-receptor mutant mice, Genes Dev., 8, 1888, 10.1101/gad.8.16.1888 · DOI
  51. St. Croix, 2000, Genes expressed in human tumor endothelium, Science, 289, 1197, 10.1126/science.289.5482.1197 · DOI
  52. Thurston, 1998, Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice, J. Clin. Invest., 101, 1401, 10.1172/JCI965 · DOI
  53. Yi, 2003, Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity, Proc. Natl. Acad. Sci. USA, in press

Cited by

Sorted by citations

Metadata

Authors
Joyce, J. A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., & Hanahan, D.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2003-11
Volume
4
Issue
5
Pages
393-403
ISSN
1535-6108
Cited by
211
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review